Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.86 |
| ▸ | CHAT | P28329 | 2/20 | 0.82 |
| ▸ | EP300 | Q09472 | 3/20 | 0.81 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.81 |
| ▸ | AURKA | O14965 | 2/20 | 0.81 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.81 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.72 |
| ▸ | NAA40 | Q86UY6 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15693003 | 1.00 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL30932695 | 1.00 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL28659513 | 1.00 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL17279149 | 1.00 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL6006469 | 0.99 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL6008385 | 0.99 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL6006360 | 0.99 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL21314173 | 0.99 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL21530730 | 0.99 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL6006403 | 0.99 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113999869-A | Promoter with expression intensity regulated by synthesis of bacterial intracellular Polyhydroxyalkanoate (PHA) and application thereof | 清华大学 | 2022-02-01 | — | — | CN | claimed |
| US-10920254-B2 | Methods and materials for producing 5 and 7-carbon monomers | INV NYLON CHEMICALS AMERICAS, LLC (US) | 2021-02-16 | — | — | US | claimed |
| US-20200283809-A1 | METHODS AND MATERIALS FOR PRODUCING 5 AND 7-CARBON MONOMERS | Invista North America S.á.r.l. | 2020-09-10 | — | — | US | claimed |
| EP-3488010-A2 | MATERIALS AND METHODS FOR DIRECTING CARBON FLUX AND INCREASED PRODUCTION OF CARBON BASED CHEMICALS | INVISTA Textiles (U.K.) Limited (GB) | 2019-05-29 | — | — | EP | claimed |
| WO-2018022440-A2 | MATERIALS AND METHODS FOR DIRECTING CARBON FLUX AND INCREASED PRODUCTION OF CARBON BASED CHEMICALS | INVISTA NORTH AMERICA S.A.R.L. (US) | 2018-02-01 | — | — | WO | claimed |
| US-20180023104-A1 | MATERIALS AND METHODS FOR DIRECTING CARBON FLUX AND INCREASED PRODUCTION OF CARBON BASED CHEMICALS | INV NYLON CHEMICALS AMERICAS, LLC | 2018-01-25 | — | — | US | claimed |
| US-20170159086-A1 | METHODS AND MATERIALS FOR PRODUCING 5 AND 7-CARBON MONOMERS | INVISTA North America S.à.r.l. | 2017-06-08 | — | — | US | claimed |
| WO-2017083493-A1 | METHODS AND MATERIALS FOR PRODUCING 5 AND 7-CARBON MONOMERS | INVISTA NORTH AMERICA S.A.R.L. (US) | 2017-05-18 | — | — | WO | claimed |
| US-20160355844-A1 | METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE | INVISTA NORTH AMERICA S.A.R.L. (US) | 2016-12-08 | — | — | US | claimed |
| US-20160355843-A1 | METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE | INVISTA NORTH AMERICA S.A.R.L. (US) | 2016-12-08 | — | — | US | claimed |
| US-20160201097-A1 | Materials and Methods of Producing 7-Carbon Monomers | INVISTA NORTH AMERICA S.A.R.L. | 2016-07-14 | — | — | US | claimed |
| EP-2861745-A2 | METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE | Invista Technologies S.à.r.l. (CH) | 2015-04-22 | — | — | EP | claimed |
| EP-2785848-A2 | METHODS FOR BIOSYNTHESIZING 1,3BUTADIENE | INVISTA Technologies S.à.r.l. (CH) | 2014-10-08 | — | — | EP | claimed |
| US-20140141482-A1 | METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE | INVISTA North America S.á r.l. (US) | 2014-05-22 | — | — | US | claimed |
| WO-2013188546-A2 | METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE | INVISTA TECHNOLOGIES S.À.R.L. (CH) | 2013-12-19 | — | — | WO | claimed |
| US-20130189753-A1 | METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE | INVISTA NORTH AMERICA S.A R.L. (US) | 2013-07-25 | — | — | US | claimed |
| WO-2013082542-A2 | METHODS FOR BIOSYNTHESIZING 1,3BUTADIENE | INVISTA NORTH AMERICA S.A.R.L. (US) | 2013-06-06 | — | — | WO | claimed |
| US-20250388910-A1 | METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL | AGAIN BIO APS (DK) | 2025-12-25 | — | — | US | disclosed |
| WO-1999000505-A1 | USE OF DNA ENCODING PLASTID PYRUVATE DEHYDROGENASE AND BRANCHED CHAIN OXOACID DEHYDROGENASE COMPONENTS TO ENHANCE POLYHYDROXYALKANOATE BIOSYNTHESIS IN PLANTS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1999-01-07 | — | — | WO | disclosed |
| WO-1998000557-A2 | METHODS OF OPTIMIZING SUBSTRATE POOLS AND BIOSYNTHESIS OF POLY-β-HYDROXYBUTYRATE-CO-POLY-β-HYDROXYVALERATE IN BACTERIA AND PLANTS | MONSANTO COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388910-A1 | METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL | ADH5, ADH1C, ADH1A | NAA50 426/4885CHAT 1999/4885EP300 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.